PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Prelude Therapeutics Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.39+0.13 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-861.3%
Net margin
-819.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +73.4% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -69.9% | -99.5% | |
| Return on assets | – | -46.4% | -62.8% | |
| Current ratio | – | 19.41 | 1.99 | |
| Capex to revenue | – | – | 0.6% | |
| Diluted shares | – | 12M | 77M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Prelude Therapeutics generated $433.51M from operations and spent $9.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$433.51M
Used
$9.69M
Capital expenditure$9.69M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-819.6%
×Asset turnover0.08×
×Equity multiplier1.58×
=Return on equity, FY2025-99.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -819.6% | 0.08× | 1.58× | -99.5% |
| FY2024 | -1816.8% | 0.03× | 1.23× | -69.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$99.50M
- Cash generatingOperating cash flow above zero-$56.30M
- Return on assets improvedROA up on the prior year-45.8% → -56.7%
- Earnings backed by cashOperating cash flow above net income-$56.30M vs -$99.50M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.30 → 1.99
- No dilutionShare count did not rise76M → 77M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.07